Anagen formulation · 4 activesBFemale-pattern-targeted multi-mechanism stack

For The Ladies

Anagen's four-active topical for female pattern hair loss: microdosed T3, estriol, minoxidil, and cetirizine 1%. This formulation does not contain spironolactone.

What's in it

Every active in For The Ladies

Each active in this formulation, scored against its own standalone evidence for AGA. Click any active for the full claim-by-claim breakdown.

Active	Grade	Why it's in this formula
Liothyronine (T3)6.5 ng/mL→Anagen induction	C	Microdosed T3 for follicular activation. Particularly relevant in female pattern hair loss given the well-documented association between thyroid dysfunction and hair loss in women.
Estriol0.02% Estrogenic adjunct	C	Topical estrogens have published evidence for female pattern hair loss. The closest analog is 17α-estradiol 0.025% (Ell-Cranell® alpha), which in a phase IV trial (n=53 women, 8 months) significantly increased hair count and diameter. Estriol is a weaker estrogen than 17α-estradiol; whether this translates to comparable scalp efficacy at 0.02% is not directly studied.
Minoxidil5%→Follicular activator	A	5% topical minoxidil is FDA-approved for female pattern hair loss with extensive RCT evidence. Carries the primary efficacy load in this formulation.
Cetirizine1% H1 antihistamine adjunct	C	Small human studies have investigated topical cetirizine 1% for pattern hair loss. In Mostafa 2021 (40 men), both cetirizine and minoxidil groups improved, but minoxidil produced greater density gains. Benefit in this specific combination has not been established.

The case for this stack

Why we paired these actives

Why these four ingredients

For The Ladies combines minoxidil 5%, liothyronine (T3) 6.5 ng/mL, estriol 0.02%, and cetirizine 1%. Minoxidil provides the established treatment foundation. The other ingredients are adjuncts with differing and more limited evidence. Published topical-estrogen studies generally use estradiol, not this estriol formulation. Cetirizine 1% has been studied in small human trials, but no randomized trial establishes the benefit of this exact four-ingredient combination. For The Ladies Max is a different formula: it also contains spironolactone and uses a higher estriol concentration.

Cited literature

Kim JH, Lee SY, Lee HJ, Yoon NY, Lee WS (2012). The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study. Ann Dermatol PMID 22879713
Choe SJ, Lee S, Choi J, Lee WS (2017). Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation. Ann Dermatol PMID 28566902
Mostafa DH, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A (2021). Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. J Pharm Pharm Sci PMID 33909554

What's been studied

The studies behind the combination

No published randomized trial of this exact four-active formulation. Studies of individual ingredients or different combinations do not establish its combined effect.

Kim 2012 — 17α-estradiol phase IV (closest topical estrogen analog)

Ann Dermatol · PMID 22879713

OPEN-LABEL

Design

Open-label, phase IV

Duration

8 months

17α-estradiol 0.025% solution applied daily produced statistically significant increases in hair count and hair diameter in Korean women with female pattern hair loss. Anagen uses estriol (not 17α-estradiol) at 0.02% — same approximate concentration, weaker estrogen.

Choe 2017 — Topical 17α-estradiol + minoxidil combination

Ann Dermatol · PMID 28566902

OBSERVATIONAL

Design

Retrospective

—

Duration

6 months

Combination of 0.025% topical 17α-estradiol + 3% topical minoxidil increased total hair count and hair caliber over 6 months in female pattern hair loss patients. Suggests topical estrogen + minoxidil pairing has additive benefit.

Honest limits

What the science doesn't yet answer

No randomized trial has tested this exact four-active formulation or established its added benefit over minoxidil alone.
Most published topical-estrogen evidence is for estradiol rather than estriol. Estriol-specific evidence at 0.02% is limited.
Long-term efficacy and safety of this exact combination are not established.

Bottom line

Our verdict on For The Ladies

Four-active combination with limited direct evidence

For The Ladies combines minoxidil with T3, estriol, and cetirizine 1%. It does not contain spironolactone. The evidence for the ingredients is not evidence that this exact combination works better than minoxidil alone.

Four ingredients, with an established minoxidil foundation and less-studied adjuncts. The complete combination remains untested.

The product